AI-generated · cited to primary sources · not investment advice
Shilpa Medicare (530549) Nov 2025 Filing Analysis
Does management do what it says?
The transcript for Q2 FY26 does not provide a specific update on the effective tax rate for the quarter, though overall profitability and PAT (INR 44 crores) were discussed. (1 not yet due, 1 in progress, 1 met across 3 tracked commitments)
“So for FY '26, we should be doing another about INR75 crores to INR100 crores from here on.”
The company expects to capture approximately 10% of the treated NAFLD population for NorUDCA over the next 3 to 5 years. — target: ~10% market share
“And with respect to clinical adoption dynamics, we expect at least we will get ~10% of the treated NAFLD populations, that will get convert to NorUDCA. This is what is our estimate over the next 3 to 5 years.”
See the full cited Management analysis of Shilpa Medicare
How durable is the business?
Regulatory standing appears to be stabilizing or improving as the company successfully completed audits for Unit 1 and is actively filing new DMFs and ANDAs across global markets. (1 stable, 1 shifted)
“Unit 1 successfully completed ANVISA (Brazil) and COFEPRIS (Mexico) regulatory audits – GMP Certificate received... 23 New DMFs filed across markets in 1HFY26”
See the full cited Business Model analysis of Shilpa Medicare
What could break the thesis?
STABLE. The company has pivoted its Aflibercept strategy. Instead of direct entry, it has out-licensed the product to two partners in India and Russia and is in discussions for the MENA region, effectively mitigating the high cost of independent global trials. (2 stable, 1 easing)
“Aflibercept: ... Out-licensed to two partners in India and Russia, with active discussions in MENA region”
See the full cited Risk analysis of Shilpa Medicare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.